肺表面活性物质救治近足月儿呼吸窘迫综合征的临床疗效观察

目的:观察肺表面活性物质在近足月儿呼吸窘迫综合征救治中的作用。方法:按照家属自愿的原则将41例确诊为新生儿呼吸窘迫综合征且胎龄介于34周-36周之间的近足月儿分为治疗组及对照组,治疗组23例,对照组18例,比较两组患儿血气分析结果、呼吸机参数、气管插管率、上机时间、存活率及住院时间。结果:治疗组患儿,用药后无论临床表现还是胸片均有不同程度的改善。用药后6小时,治疗组PaO2及PaCO2均优于对照组(P<0.05);比较两组中机械通气患儿呼吸机参数,治疗组明显低于对照组(P<0.05);治疗组气管插管率明显低于对照组,且上机时间(nCPAP、nIPPV、气管插管机械通气)也较对照组明显缩短(P<0.05),但两组患儿存活率及住院时间差异无统计学意义。结论:对于近足月呼吸窘迫综合征患儿,尽早明确诊断并在发病早期给予PS替代治疗,可提高此类患儿的生存率及预后,对降低早产儿病死率有重要意义!     

CPAP联合肺表面活性物治疗新生儿呼吸窘迫综合征的临床疗效及对患者血气指标的影响

目的:探讨CPAP(Continuous Positive Airway Pressure)联合肺表面活性物质治疗新生儿呼吸窘迫综合征(NRDS)临床疗效及对血气指标的影响。方法:选择2014年8月至2018年8月本院收治的新生儿呼吸窘迫综合征患者200例,将其随机分为2组,每组100例。A组给予CPAP(持续正压通气)联合肺表面活性物质治疗,B组给予CPAP(持续正压通气)治疗,分析和比较两组的临床疗效及治疗前后血气指标的变化。结果:治疗后,两组新生儿患者PaO_2均较治疗前均显著升高,PaCO_2较治疗前明显降低,且A组PaO_2显著高于B组(P0.05),PaCO_2显著低于B组(P0.05);A组住院时间显著短于B组(P0.05),临床总有效率显著高于B组(P0.05);两组新生儿患者的胸部X线评分均较治疗前显著降低(P0.05),A组12 h和24 h胸部X线评分均显著性低于B组(P0.05);A组PEEP/cmH_2O水平显著低于B组(P0.05),Fi O_2水平显著高于B组(P0.05);两组生儿患者的的OI指数均较治疗前显著升高,且A组明显高于B组(P0.05)。结论:CPAP联合肺表面活性物质治疗NRDS的临床效果显著优于单用CPAP(持续正压通气)治疗,且且可显著改善患儿血气指标。     

两种肺表面活性物质治疗新生儿呼吸窘迫综合症的临床疗效比较

目的:比较珂立苏与固尔苏两种肺表面活性物质(PS)治疗新生儿呼吸窘迫综合症(NRDS)的临床疗效.方法:选择2011年2月～2012年12月在我院确诊并接受治疗的NRDS患儿58例,在患儿家长知情同意的情况下,随机分为A组(n=26例)和B组(n=32例).在给予相同基础治疗措施的情况下,A组患儿采用珂立苏治疗,B组患儿采用固尔苏治疗,比较两组患儿治疗24h后的机械通气参数与血气指标的变化,并比较两组患儿症状缓解时间、机械通气时间、吸氧治疗时间及住院时间.结果:治疗24h后,两组患儿的呼气末正压(PEEP)、吸氧峰压(PIP)、平均气道压力(MAP)和氧浓度(FiO2)比较,均较治疗前显著降低,且B组以上指标均显著低于A组,差异均具有统计学意义(P＜0.05);两组患儿的血PaO2和pH值均较治疗前显著升高,而血PaCO2、氧合指数(OI)均较治疗前显著降低,且B组血PaO2、pH值和OI均显著高于A组,而血PaCO2显著低于A组,差异具有统计学意义(P＜0.05).此外,B组患儿经治疗后的症状缓解时间、机械通气时间、吸氧治疗时间及住院时间均较A组患儿显著缩短,差异均具有统计学意义(P＜0.05).结论:积极给予固尔苏治疗NRDS,可促进患儿机械通气参数与血气指标的改善,并缩短临床治疗时间,其效果优于珂立苏.     

肺泡表面活性物质联合机械通气治疗新生儿呼吸窘迫综合征的护理体会

目的探讨肺泡表面活性物质(PS)联合机械通气治疗新生儿呼吸窘迫综合征(NRDS)的临床护理方法。方法对我院2010年6月～2012年12月NICU住院的55例NRDS患儿使用改良方法气管内注入PS联用呼吸机治疗,并观察其疗效。结果该法的疗效确切,明显缩短病程,有效地减少给药过程中缺氧现象的发生,减少住院时间及治疗费用,降低死亡率,而且安全性好。结论早期、足量用药并联用机械通气能有效治疗新生儿呼吸窘迫综合征,正确的护理措施能提高治疗的有效率。     

肺表面活性物质治疗新生儿呼吸窘迫综合征前给予nCPAP呼吸支持最佳时间窗的临床研究

摘要 目的：探讨肺表面活性物质（PS）治疗新生儿呼吸窘迫综合征（NRDS）前给予经鼻持续气道正压通气（nCPAP）呼吸支持的最佳时间窗。方法：选择2017年1月至2019年12月期间我院收治的NRDS患儿100例。根据随机数字表法分为A组（给予PS前预先进行小于2 h的nCPAP,n=33）、B组（给予PS前预先进行2-4 h的nCPAP,n=33）和C组（立即给予PS,n=34）。对比三组患儿的血气分析指标、肺功能指标、临床指标和并发症发生率。结果：A组、B组给予PS后4h、给予PS后24 h动脉血氧分压（PaO₂）、pH值高于C组,且B组高于A组（P<0.05）,而动脉二氧化碳分压（PaCO₂）低于C组,且B组低于A组（P<0.05）。A组、B组给予PS后4 h、给予PS后24 h潮气量（VT）、肺动态顺应性（CD）高于C组,且B组高于A组（P<0.05）,而吸气阻力（Raw）低于C组,且B组低于A组（P<0.05）。B组用药后3天内需气管插管行机械通气例数少于A组和C组,住院时间短于A组和C组（P<0.05）,A组、C组的用药后3天内需气管插管行机械通气例数、住院时间对比无明显差异（P>0.05）。三组患儿并发症发生率未见统计学差异（P>0.05）。结论：给予PS前预先进行2-4h的nCPAP,可较好地改善患儿血气分析指标和肺功能,有助于改善患儿预后。     

微创肺表面活性物质对呼吸窘迫综合征新生儿肝肾功能、氧合功能及呼吸功能的影响

目的:探讨微创肺表面活性物质(pulmonary surfactant,PS)对呼吸窘迫综合征新生儿氧合功能、肝肾功能及呼吸功能的影响。方法:选择2018年3月至2019年3月我院收治的66例新生呼吸窘迫综合征的患儿作为研究对象,并按照随机数字表法分为观察组(n=33)和对照组(n=33)。对照组患儿采取常规的治疗方式,观察组患儿则在对照组治疗基础上应用微创PS治疗。观察比较两组患儿的动脉血气指标、Ⅱ型肺泡细胞表面抗原(KL-6)、巨噬细胞移动抑制因子-1(MIF-1)、高迁移率族蛋白1(HMGB-1)、肝肾功能、氧合指数及呼吸机参数。结果:治疗后,两组的氧分压(PaO_2)、二氧化碳总量(TCO_2)、氧饱和度(SaO_2)均较治疗前显著增高;且观察组以上指标均高于对照组。两组的Ⅱ型肺泡细胞表面抗原(KL-6)、巨噬细胞移动抑制因子-1 (MIF-1)、高迁移率族蛋白1(HMGB-1)均较治疗前显著降低,且观察组的以上指标均低于对照组。两组的谷草转氨酶(AST)、谷丙转氨酶(ALT)、尿素氮(BUN)、肌酐(CRE)水平均较治疗前显著降低,且观察组的以上指标均明显低于对照组。观察两组的呼吸机参数和氧合指数,发现两组的吸入氧浓度(FiO_2)、吸气峰压(PIP)、呼吸末正压(PEEP)、氧合指数(PaO_2/FiO_2,OI)均较治疗前有所改善,且观察组的以上指标均要优于对照组(P0.05)。结论:应用微创PS治疗新生儿呼吸窘迫综合征的效果显著,能明显改善患儿的动脉血气指标、肝肾功能以及氧合功能,减轻炎症反应,并减少机械通气的参数。     

珂立苏联合经鼻间歇性正压通气(NIPPV)治疗新生儿呼吸窘迫综合征46例临床分析

目的:研究珂立苏(肺表面活性物质)联合经鼻间歇性正压通气(NIPPV)治疗新生儿呼吸窘迫综合征(NRDS)的临床效果.方法:选取2010年4月-2012年4月我院NICU收治的符合NRDS诊断标准的患儿46例,将患儿随机分为试验组29例和对照组17例.试验组患儿给予珂立苏联合NIPPV治疗,对照组患儿仅给予NIPPV治疗.比较两者患儿治疗前及治疗后6h、24h、48h呼吸功能参数变化情况、X线胸片评分改变情况及3d内存活率.结果:(1)呼吸功能参数情况:试验组患儿上机时(用药前)及用药后6h、24h、48h后肺顺应性(C值)随通气时间进展而逐渐升高,氧合指数(OI值)、呼吸指数(RI值)及肺泡-动脉氧分压差((A-a)DO2值)均随通气时间进展而逐渐下降.试验组患儿经珂立苏治疗后6h、24h、48h和对照组比较,C值均显著高于对照组(P＜0.01),OI值均显著低于对照组(P＜0.01),RI值均显著低于对照组(P＜0.01),(A-a)DO2值均显著低于对照组(A-a)DO2值.(2)X线胸片变化:试验组患儿上机时(用药前)及用药后6h、24h、48h后X线胸片评分逐渐降低,且用药后6h、24h、48h后每一时间点评分均显著低于对照组(P＜0.05).(3)患儿3d内存活率:试验组患儿存活率96.4％显著高于对照组70.1％(P＜0.05).结论:肺表面活性物质(珂立苏)联合经鼻间歇性正压通气(NIPPV)能明显改善患儿肺通气、换气功能,降低患儿死亡率,治疗新生儿呼吸窘迫综合征临床疗效显著优于单纯应用NIPPV治疗.     

肺表面活性物质的研究

肺表面活性物质的研究□刘桂萍（吉林省白城师范高等专科学校生物系，白城１３７０００）□付晶（吉林省长春市宽城区中医院，长春１３００５１）肺表面活性物质（ｐｕｌｍｏｎａｒｙｓｕｒｆａｃｔａｎｔ，ＰＳ）这一概念首先是由德国生理学家ＶｏｎＮｅｅ－ｇａａｒｄ在...     

早期与晚期应用肺表面活性物质联合经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征的比较研究

目的:比较早期与晚期应用肺表面活性物质(Ps)联合经鼻持续气道正压通气(NCPAP)治疗新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法:选取海南省三亚市人民医院于2014年1月～2018年7月期间收治的NRDS患儿100例,根据随机数字表法将患儿分为对照组(n=50)和研究组(n=50),对照组给予NCPAP治疗,研究组在对照组基础上联合Ps治疗,并根据Ps注入时间的不同将研究组患儿分为早期组(出生6h内注入,n=25)和晚期组(出生6～12h注入,n=25)。观察并比较对照组、早期组、晚期组患儿的临床疗效,并比较三组患儿治疗前、治疗1d后动脉血酸碱度(pH)、动脉二氧化碳分压(PCO_2)、动脉血氧分压(PO_2)、呼气末正压通气(PEEP)、吸入氧浓度(FiO_2)以及并发症发生情况。结果:早期组患儿临床总有效率高于对照组、晚期组(P0.05);而对照组、晚期组患儿临床总有效率比较差异无统计学意义(P0.05)。治疗1d后,三组患儿PCO_2较治疗前降低,PO_2较治疗前升高,且早期组PCO_2低于对照组、晚期组,PO_2高于对照组、晚期组(P0.05);但对照组、晚期组PCO_2、PO_2比较差异无统计学意义(P0.05)。治疗1d后,三组患儿PEEP、FiO_2较治疗前降低,且早期组低于对照组、晚期组(P0.05);但对照组、晚期组PEEP、Fi O2比较差异无统计学意义(P0.05)。三组患儿并发症总发生率比较差异无统计学意义(P0.05)。结论:与晚期相比,早期应用Ps联合NCPAP治疗NRDS疗效确切,其改善患儿血气指标及NCPAP参数的效果更佳,同时不会增加不良反应。     

危重症新生儿肾上腺皮质功能状态的研究

目的:研究危重症新生儿肾上腺皮质功能状态、肾上腺皮质功能不全(AI)的发生率及其与患儿预后的关系。方法:选择我科收治的日龄2天的危重症新生儿52例(其中早产儿23例,足月儿29例),根据新生儿危重病例评分(NCIS)分为轻度危重组和重度危重组,分别检测其血清基础皮质醇和小剂量促肾上腺皮质激素(ACTH)刺激实验30分钟后的清皮质醇峰值。血清基础皮质醇15μg/dl为合并AI。结果:危重症早产儿基础皮质醇浓度及小剂量ACTH刺激实验前后皮质醇差值均较足月儿组低[(15.08±4.98)μg/dl vs(19.65±9.18)μg/dl,P=0.027;(12.06±3.71)μg/dl vs(19.09±4.75)μg/dl,P=0.000]。危重症新生儿合并AI的发生率为38.5%,其中早产儿组为47.8%,足月儿组为34.5%。AI组新生儿死亡2例,未发现AI与患儿的死亡率有关。结论:危重症早产儿肾上腺皮质功能较足月儿差。危重症新生儿合并AI的发生率较高,但与患儿的死亡率无关。     

肺表面活性物质及其在肺感染作用中的研究进展

肺表面活性物质是位于肺泡上皮细胞表面的由关键性脂质蛋白质组成的具有多种功能的复合物。肺表面活性物质中各组成部分的联合效应是肺保持稳定性和宿主防御传染病病原体的基础。在此,就肺表面活性物质的主要成分、结构、功能及其与肺感染的关系做一简要综述。     

Effects of Antioxidants on Surfactant Peroxidation by Stimulated Human Polymorphonuclear Leukocytes

Production of oxygen radicals by stimulated phagocytes followed by surfactant lipid peroxidation (LPO) and loss of surfactant function have all been implicated in the pathogenesis of acute lung injury. We studied the interactions between natural lung surfactant (Curosurf) and neutrophils in vitro, and compared various antioxidants; (superoxide dismutase (SOD), vitamin E, vitamin C, ebselen and melatonin), or combinations of them in duplicate and triplicate regarding their ability to decrease superoxide production and the peroxidation level of surfactant caused by activated phagocytes. The superoxide production of neutrophils activated by Candida albicans was measured with the nitroblue tetrazolium (NBT) test. The subsequent LPO was estimated as the content of malondialdehyde (MDA) and 4-hydroxyalkenals (4-HNE). We found that lung surfactant decreased the superoxide production by activated neutrophils (29.7%) and that Curosurf was peroxidized with elevated MDA/4-HNE values. With supplements of antioxidants (except vitamin C), superoxide radical production and the surfactant LPO level fell in a dose-dependent manner. The protective effect of the antioxidants differed in each test. SOD had a slight effect in both tests. The findings with vitamin E, melatonin and ebselen were similar. The best combination was that of a natural and a synthetic antioxidant (melatonin-ebselen) with a 60% decrease in comparison to the corresponding control. These findings suggest that antioxidants, particularly in combination, prevent LPO of lung surfactant.     

Exploration of green integrated approach for effluent treatment through mass culture and biofuel production from unicellular alga,Acutodesmus obliquus RDS01

Abstract

This study deals with the open pond (OP) pilot scale treatment of cassava effluent and enhancement of Ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO) enzyme through CO₂ utilization by the microalga, Acutodesmus obliquus RDS01. The cassava effluent treatment (ET) revealed maximum reduction of ammonia (96.8%), calcium (94.6%), chloride (95.2%), chlorine (98.5%), inorganic phosphate (94.6%), magnesium (96.8%), nitrate (96.89%), organic carbon (95.9%), organic phosphorus (96.3%), potassium (97.9%), sodium (97.1%), and sulfate (95.4%) on 15^th day using A. obliquus. The microalga produced highest RuBisCO enzyme activity (90%), CO₂ utilization efficiency (95%), biomass (8.9 gL^?1), lipid (176.65?mg mL^?1), carbohydrate (96.78?mg mL^?1), biodiesel (4.1?mL g^?1), and bioethanol (3.7?mL g^?1) during OP treatment. The isolated RuBisCO gene (rbcL) was used to construct the protein model by homology modeling. The microalgal-lipid content was analyzed through thin layer chromatography, the biodiesel produced was analyzed using Fourier-transform infrared spectroscopy and gas chromatography mass spectrometry (GCMS). The bioethanol production was confirmed by high performance liquid chromatography and GCMS analyses. A. obliquus produced of 98.75% biodiesel and 96.83% bioethanol in the OP pilot scale treatment A. obliquus. Overall, the microalga A. obliquus could act as an effective CO₂ capturing and bioremediation agent in the cassava ET, and also for the biodiesel and bioethanol can be produced.     

Surfactant and its role in the pathobiology of pulmonary infection

Pulmonary surfactant is a complex surface-active substance comprised of key phospholipids and proteins that has many essential functions. Surfactant's unique composition is integrally related to its surface-active properties, its critical role in host defense, and emerging immunomodulatory activities ascribed to surfactant lipids. Together these effector functions provide for lung stability and protection from a barrage of potentially virulent infectious pathogens.     

Role of Peripheral Benzodiazepine Receptors on Secretion of Surfactant in Guinea Pig Alveolar Type II Cells

Granular type II cells located in the alveolar epithelium synthesize and secrete pulmonary surfactant and have specialized ion transport system. Alveolar type II cells are stimulated to secrete pulmonary surfactant by a variety of agonists. One mechanism by which extracellular signals are perceived by cells is the mobilization of intracellular Ca²⁺. Peripheral benzodiazepine receptors (PBRs) are present in both peripheral tissues and central nervous system. We have previously reported the presence of high density PBRs in lung and alveolar type II cells. It is known that both PBRs and beta-adrenergic receptors (beta-ARs) play an important role in cellular Ca²⁺ transport. Furthermore, we have suggested earlier that PBRs are someway functionally associated with the beta-ARs. The objective of the present study was to determine whether PBRs play any role in the secretion of surfactant by alveolar type II cells. Alveolar type II cells were isolated from normal weanling guinea pigs by panning method and incubated with ³H-palmitic acid in minimum essential medium to synthesize labelled dipalmitoyl phosphatidylcholine (DPPC). After washing, the cells were treated at 37°C for one hour with 10 M isoproterenol (IP) in the presence and absence of 10 M Ro 5-4864, an agonist for PBRs. After one hour, the release of labelled DPPC in the medium was analyzed. The control cells released DPPC without any addition of a ligand. However, the treatment of cells with IP, Ro 5-4864 and IP + Ro 5-4864 caused 24, 52 and 171% increase in the secretion of DPPC, respectively. In another experiment, type II cells were loaded with Fura-2 dye and treated with either IP or epineprine or Ro 5-4864. Both isoproterenol and epinephrine caused a significant increase in the level of cytosolic free Ca²⁺. However, Ro 5-4864 caused not only a decrease in the level of cytosolic free Ca²⁺ but also counteracted the stimulatory effect of IP. This may suggest that while ligands for ARs stimulate Ca²⁺ release into cytosol, the ligand for PBRs stimulates efflux of Ca²⁺ in alveolar type cells. Thus, the increased secretion of surfactant by the ligand of PBRs in alveolar type II cells may be mediated through its effects on increased Ca²⁺ efflux.     

Transient Exposure of Pulmonary Surfactant to Hyaluronan Promotes Structural and Compositional Transformations into a Highly Active State

Pulmonary surfactant is a lipid-protein complex that lowers surface tension at the respiratory air-liquid interface, stabilizing the lungs against physical forces tending to collapse alveoli. Dysfunction of surfactant is associated with respiratory pathologies such as acute respiratory distress syndrome or meconium aspiration syndrome where naturally occurring surfactant-inhibitory agents such as serum, meconium, or cholesterol reach the lung. We analyzed the effect of hyaluronan (HA) on the structure and surface behavior of pulmonary surfactant to understand the mechanism for HA-promoted surfactant protection in the presence of inhibitory agents. In particular, we found that HA affects structural properties such as the aggregation state of surfactant membranes and the size, distribution, and order/packing of phase-segregated lipid domains. These effects do not require a direct interaction between surfactant complexes and HA and are accompanied by a compositional reorganization of large surfactant complexes that become enriched with saturated phospholipid species. HA-exposed surfactant reaches very high efficiency in terms of rapid and spontaneous adsorption of surfactant phospholipids at the air-liquid interface and shows significantly improved resistance to inactivation by serum or cholesterol. We propose that physical effects pertaining to the formation of a meshwork of interpenetrating HA polymer chains are responsible for the changes in surfactant structure and composition that enhance surfactant function and, thus, resistance to inactivation. The higher resistance of HA-exposed surfactant to inactivation persists even after removal of the polymer, suggesting that transient exposure of surfactant to polymers like HA could be a promising strategy for the production of more efficient therapeutic surfactant preparations.     

Evaluation of RDS/Peripherin and ROM1 as candidate genes in generalised progressive retinal atrophy and exclusion of digenic inheritance

Generalised progressive retinal atrophy (gPRA) is a heterogeneous group of hereditary diseases causing degeneration of the retina in dogs and cats. As a combination of mutations in the RDS/Peripherin and the ROM1 genes leads to the phenotype of retinitis pigmentosa in man we first performed mutation analysis to screen these genes for disease causing mutations followed by the investigation of a digenic inheritance in dogs. We cloned the RDS/Peripherin gene and investigated the RDS/Peripherin and ROM1 genes for disease causing mutations in 13 gPRA-affected dog breeds including healthy animals, obligate gPRA carriers and gPRA-affected dogs. We screened for mutations using single strand conformation polymorphism (SSCP) analysis. Sequence analysis revealed several sequence variations. In the coding region of the RDS/Peripherin gene three nucleotide exchanges were identified (A277C; C316T; G1255A), one of which leads to an amino acid substitution (Ala339Thr). Various silent sequence variations were found in the coding region of the ROM1 gene (A536G, G1006A, T1018C, T1111C, C1150T, C1195T), as well as an amino acid substitution (G252T; Ala54Ser). By excluding the respective gene as a cause for gPRA several sequence variations in the intronic regions were investigated. None of these sequence variations cosegregated with autosomal recessively (ar) transmitted gPRA in 11 breeds. The candidate gene RDS/Peripherin obviously does not harbour the critical mutation causing the autosomal recessive form of gPRA because diseased individuals show heterozygous genotypes for sequence variations in the Miniature Poodle, Dachshund, Australian Cattle Dog, Cocker Spaniel, Chesapeake Bay Retriever, Entlebucher Sennenhund, Sloughi, Yorkshire Terrier, Tibet Mastiff, Tibet Terrier and Labrador Retriever breeds. In the following breeds the ROM1 gene was also excluded indirectly for gPRA: Miniature Poodle, Dachshund, Australian Cattle Dog, Sloughi, Collie, Tibet Terrier, Labrador Retriever and Saarloos/Wolfhound. Digenic inheritance for gPRA is practically excluded for both these genes in four breeds: Miniature Poodle, Dachshund, Labrador Retriever and Saarloos/Wolfhound.